Ali Gholamrezanezhad

Ali Gholamrezanezhad, MD, specialist of nuclear medicine and molecular imaging from Tehran University of Medical Sciences and Fellow of the European Board on Nuclear Medicine (FEBNM) is the author of more than 60 publications in the field of nuclear medicine. He currently is involved in research activities in department of nuclear medicine at Johns Hopkins University. He has published in almost all nuclear medicine journals, including Journal of Nuclear Medicine, European Journal of Nuclear Medicine, Clinical Nuclear Medicine, Journal of Nuclear Cardiology, Journal of Nuclear Medicine technology, Nuclear Medicine Communications, Nucklearmedizine, Annals of Nuclear Medicine, Hellenic Journal of Nuclear Medicine, Nuclear Medicine and Biology, Revista Espanola de Medicina Nucleare, and Iranian Journal of Nuclear Medicine. He serves as a reviewer or member of editorial board for a number of international journals, such as Rare Tumors, Clinical Neurology and Neurosurgery, Anatolian Journal of Cardiology.

Ali Gholamrezanezhad

1books edited

Latest work with IntechOpen by Ali Gholamrezanezhad

The development of nuclear medicine as a medical specialty has resulted in the large-scale application of its effective imaging methods in everyday practice as a primary method of diagnosis. The introduction of positron-emitting tracers (PET) has represented another fundamental leap forward in the ability of nuclear medicine to exert a profound impact on patient management, while the ability to produce radioisotopes of different elements initiated a variety of tracer studies in biology and medicine, facilitating enhanced interactions of nuclear medicine specialists and specialists in other disciplines. At present, nuclear medicine is an essential part of diagnosis of many diseases, particularly in cardiologic, nephrologic and oncologic applications and it is well-established in its therapeutic approaches, notably in the treatment of thyroid cancers. Data from official sources of different countries confirm that more than 10-15 percent of expenditures on clinical imaging studies are spent on nuclear medicine procedures.

Go to the book